Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, January 31, 2023
[ Tue, Jan 31st 2023
] - WOPRAI
[ Tue, Jan 31st 2023
] - WOPRAI
[ Tue, Jan 31st 2023
] - WOPRAI
[ Tue, Jan 31st 2023
] - WOPRAI
[ Tue, Jan 31st 2023
] - WOPRAI
[ Tue, Jan 31st 2023
] - WOPRAI
[ Tue, Jan 31st 2023
] - WOPRAI
[ Tue, Jan 31st 2023
] - WOPRAI
[ Tue, Jan 31st 2023
] - WOPRAI
[ Tue, Jan 31st 2023
] - WOPRAI
[ Tue, Jan 31st 2023
] - WOPRAI
[ Tue, Jan 31st 2023
] - WOPRAI
[ Tue, Jan 31st 2023
] - WOPRAI
[ Tue, Jan 31st 2023
] - WOPRAI
[ Tue, Jan 31st 2023
] - WOPRAI
[ Tue, Jan 31st 2023
] - WOPRAI
[ Tue, Jan 31st 2023
] - WOPRAI
[ Tue, Jan 31st 2023
] - WOPRAI
[ Tue, Jan 31st 2023
] - WOPRAI
[ Tue, Jan 31st 2023
] - WOPRAI
[ Tue, Jan 31st 2023
] - WOPRAI
[ Tue, Jan 31st 2023
] - WOPRAI
[ Tue, Jan 31st 2023
] - WOPRAI
[ Tue, Jan 31st 2023
] - WOPRAI
[ Tue, Jan 31st 2023
] - WOPRAI
[ Tue, Jan 31st 2023
] - WOPRAI
[ Tue, Jan 31st 2023
] - WOPRAI
[ Tue, Jan 31st 2023
] - WOPRAI
[ Tue, Jan 31st 2023
] - WOPRAI
[ Tue, Jan 31st 2023
] - WOPRAI
Neena Bitritto-Garg Maintained (ACAD) at Hold with Increased Target to $19 on, Jan 31st, 2023
Neena Bitritto-Garg of Citigroup, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Hold with Increased Target from $17 to $19 on, Jan 31st, 2023.
Neena has made no other calls on ACAD in the last 4 months.
There are 6 other peers that have a rating on ACAD. Out of the 6 peers that are also analyzing ACAD, 3 agree with Neena's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Uy Ear of "Mizuho" Maintained at Hold with Decreased Target to $15 on, Wednesday, December 21st, 2022
- Tessa Romero of "JP Morgan" Maintained at Hold with Decreased Target to $17 on, Monday, November 14th, 2022
- Esther Hong of "Loop Capital" Initiated at Hold and Held Target at $17 on, Tuesday, November 1st, 2022
These are the ratings of the 3 analyists that currently disagree with Neena
- Yatin Suneja of "Guggenheim" Upgraded from Hold to Strong Buy and Held Target at $22 on, Tuesday, January 3rd, 2023
- Salveen Richter of "Goldman Sachs" Downgraded from Hold to Strong Sell and Decreased Target to $12 on, Friday, November 4th, 2022
- Gregory Renza of "RBC Capital" Maintained at Buy with Decreased Target to $21 on, Thursday, November 3rd, 2022
